An eye chart on a navy background whose top rows are sharp while the lower rows blur and fade into black, beside the headlines "Ozempic Blindness Lawsuits" and "What the Data on NAION Shows."

A Massachusetts Man Says Ozempic Blinded Him. Now the FDA Requires a NAION Warning on Every GLP-1.

November 08, 2026•10 min read

By Kate Dee, MD — Founder, MedSpa Board

Updated November 18, 2026: On November 9, the FDA required the makers of every GLP-1 drug to add NAION to the Warnings and Precautions section of the label. This post has been updated with the FDA’s action and the data behind it.

Edward Gillen of Dedham, Massachusetts, took Ozempic between 2024 and 2025. In the spring of 2025, he lost his sight. His lawsuit says he lost vision in both eyes from non-arteritic anterior ischemic optic neuropathy, or NAION, and that the loss is permanent.

Gillen, a father of four and a longtime state highway worker, told Boston 25 News that he knew the drug had side effects. “Because you hear it on the commercials, you hear an advertiser, your doctor tells you them,” he said. “But not this. Not this.”

His complaint against Novo Nordisk, the maker of Ozempic, says he would not have used the drug if he had been told about a possible increased risk of NAION. Novo Nordisk says lawsuits like his are without merit. Nothing has been proven in court.

The short version: the FDA now considers the risk serious enough to put on the label, it is very small, and nobody knows the true number yet.

NAION is a stroke of the optic nerve, and there is no treatment for it

In NAION, the blood supply to the front of the optic nerve drops and part of the nerve is damaged. Mass General Brigham ophthalmologist Dr. Joseph Rizzo has compared it to a stroke of the optic nerve.

It typically happens without pain or warning, in one eye, and many patients notice it when they wake up. The classic pattern is loss of the upper or lower half of the visual field. According to the American Academy of Ophthalmology, about 70 percent of patients stay where they are, about 20 percent improve modestly, and about 10 percent get worse over the first few weeks. About 15 percent have the other eye affected within five years. No treatment has been shown to improve the outcome.

The risk factors are familiar to anyone who treats weight loss patients: diabetes, high blood pressure, high cholesterol, smoking, sleep apnea, and the erectile dysfunction drugs sildenafil and tadalafil. The biggest anatomic factor is a small, crowded optic disc, often called a “disc at risk.” Most people who have one do not know it.

NAION was rare long before GLP-1s existed: an estimated 2.3 to 10.2 cases per 100,000 people over age 50 per year in the U.S., with an average age in the mid-60s.

Nearly 280 GLP-1 vision loss lawsuits are now consolidated in one federal court in Philadelphia

In December 2025, the federal NAION lawsuits against GLP-1 makers were consolidated into MDL No. 3163 in the Eastern District of Pennsylvania under Judge Karen Marston. The proceeding covers Novo Nordisk’s semaglutide products (Ozempic, Wegovy, Rybelsus) and Eli Lilly’s tirzepatide products (Mounjaro, Zepbound). When Gillen’s case was reported in late September, it was one of more than 130. By early November, plaintiff firms tracking the docket counted about 280. There have been no trials or settlements, and the major motions over expert testimony are not expected until July 2027.

The legal theory is failure to warn: the manufacturers knew or should have known about a NAION risk and did not put it on the label. Until this month, the plaintiffs’ strongest fact was that other regulators had acted and the FDA had not. The European Medicines Agency concluded in June 2025 that NAION is a “very rare” side effect of semaglutide, affecting up to 1 in 10,000 users, and required a label update. The World Health Organization issued an alert the same month, the U.K.’s MHRA updated its guidance in February 2026, and Australia’s TGA updated GLP-1 product information in July 2026, noting that the evidence may support a signal for semaglutide but not for tirzepatide.

On November 9, the FDA required a NAION warning on every GLP-1 label, tirzepatide included

The FDA’s Drug Safety Communication requires the makers of every GLP-1 receptor agonist to add NAION to the Warnings and Precautions section of the label. It covers exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, tirzepatide and orforglipron, whether the drug is sold for diabetes or weight loss.

The FDA pooled 126 randomized trials covering 134,253 patients and 288,879 person-years. It found 15 probable cases of NAION: 10 on a GLP-1 and 5 on placebo, or 6.4 versus 3.8 cases per 100,000 person-years. In the FDA’s Sentinel database of patients with type 2 diabetes, GLP-1s carried a higher risk than DPP-4 inhibitors and no statistically significant difference from SGLT2 inhibitors.

The FDA’s language is measured. It describes a “potential increased risk of rare NAION events,” says the cause is “not completely understood,” and found no mechanism in animal studies. It tells prescribers to have patients report sudden, painless vision loss in one eye right away, to refer suspected NAION promptly to an ophthalmologist, and to consider stopping the GLP-1 in a patient who develops NAION unless the benefits clearly outweigh the risk. Patients who have already had NAION face a higher risk of recurrence.

The warning does not decide the lawsuits. The courts still have to decide whether these drugs cause NAION at all, and whether they caused it in each plaintiff.

The first study reported a four- to seven-fold risk. Much larger studies found far less.

The concern started with a July 2024 study in JAMA Ophthalmology by researchers at Mass Eye and Ear, including Dr. Rizzo. Among 16,827 patients at their hospital, semaglutide was associated with a 4.28 times higher risk in patients with diabetes and 7.64 times higher in patients with overweight or obesity.

Those numbers made headlines. The size of the study did not. The comparisons involved 710 patients with diabetes and 979 with overweight or obesity, and the weight loss result rested on 20 cases in the semaglutide group and 3 in the comparison group. More than 8 percent of the semaglutide patients with diabetes developed NAION over three years, far above any population rate, which tells you these were not typical patients. The authors wrote that more research was needed to determine whether semaglutide causes NAION.

A February 2025 study in JAMA Ophthalmology pooled 14 databases covering 37.1 million adults with type 2 diabetes. NAION occurred in semaglutide users at 14.5 per 100,000 person-years, and the increase over three other diabetes drugs was not statistically significant under the broader definition of NAION.

An August 2025 study in JAMA Network Open matched 159,398 patients with type 2 diabetes. Over two years, NAION occurred in 0.04 percent of patients on semaglutide or tirzepatide and 0.02 percent on other diabetes drugs.

A 2026 meta-analysis in Ophthalmology combined 8 observational studies of more than 1.6 million people and 8 randomized trials of 31,174. In the observational diabetes studies, NAION occurred at 26.7 cases per 100,000 person-years in semaglutide users and 18.9 in nonusers. The randomized trials showed no statistically significant difference. A pooled analysis of Novo Nordisk’s own placebo-controlled trials, published in April 2026, also found no increase.

Some of the signal may be noise. A September 2026 preprint, not yet peer reviewed, found that FDA adverse event reports of NAION with semaglutide were nearly nonexistent through 2023, then rose sharply in 2024, the year the Mass Eye and Ear study made headlines. That pattern is typical of publicity-driven reporting.

Even with a label warning, NAION on a GLP-1 is a one-in-tens-of-thousands event

In absolute terms, the FDA’s pooled trials show 2.6 extra cases per 100,000 person-years, about one extra case for every 38,000 people treated for a year. The observational diabetes studies put it higher, about one extra case for every 10,000 to 13,000 people, in line with the EMA’s “up to 1 in 10,000.” Doubling a very rare event still leaves a very rare event.

The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society reached the same view in May 2026: a possible association, causation not established, and no reason to stop GLP-1 therapy automatically. Dr. Rizzo has said, “I would not take my findings and use them to recommend that patients stop taking their medications.”

The real number may be one extra case in 10,000, one in 40,000, or close to zero. What is certain is that NAION is extremely rare, with or without a GLP-1.

Prescribers of Wegovy, Zepbound and compounded GLP-1s: put NAION in your consent form

Most medspa weight loss patients are not diabetic, and most of the evidence comes from patients with type 2 diabetes, who already carry a higher baseline risk. For weight loss patients, the estimates range from 7.64 times higher in the small Mass Eye and Ear study to no significant increase in the 2026 meta-analysis. Tirzepatide has very little data of its own, and the FDA included it in the warning anyway. Without a known mechanism, there is no basis for saying one GLP-1 is safer than another for the optic nerve.

We do not know whether compounded semaglutide and tirzepatide carry exactly the same risk as the brand-name drugs, because no study has looked. There is also no reason to believe they don’t.

Anyone prescribing these drugs, brand-name or compounded, should include NAION in the consent form. Before starting, ask about prior NAION, unexplained vision loss in one eye, sleep apnea, and use of sildenafil or tadalafil. Tell every patient that sudden, painless vision loss in one eye means a call to your office and an eye exam the same day.

The FDA needed 134,000 trial patients to find 15 cases of NAION

This is why drugs have to be studied in very large populations. A one-in-10,000 risk cannot be seen in a trial of a few thousand people. Fifteen cases across 126 trials is enough to raise a flag and not enough to settle the question.

Ozempic was approved in 2017. The NAION question did not emerge until 2024, after millions of people had used semaglutide and researchers could search hospital records, insurance claims and national registries in Denmark and Norway. The U.S. label changed this month, nine years after approval. That is the approved drug system doing what it is designed to do: trials, approval, surveillance, and label changes when rare risks surface. It is slow and imperfect, but it is the only process that can find a risk this small.

Peptides have never been studied, so their risks, large or small, are unknown

Now apply that standard to peptides. BPC-157, CJC-1295, ipamorelin and the other peptides sold through medspas, wellness clinics and websites have never been through the trials that semaglutide went through. There is no approved label, no registry, and no one collecting adverse events. In October 2026, HHS announced it will let pharmacies compound six unapproved peptides. That changes who may make them. It does not create a single piece of safety data.

With GLP-1s, the argument is whether a risk is one in 10,000, one in 40,000 or nearly zero. That argument is only possible because the drugs were studied in tens of thousands of people and tracked in millions more. For peptides, we cannot estimate the common side effects, let alone a rare one. In October, a coroner in Australia found that unapproved peptides triggered the fatal anaphylaxis of actor Richard Norton. A rare and serious reaction like that is exactly what no peptide has been studied closely enough to measure. No one can tell a patient a peptide is safe, because nobody has done the work to know.

Patients on a GLP-1: sudden vision loss in one eye means an eye exam today

If you lose vision suddenly, even partly, even without pain, see an eye doctor that day. Go to an emergency room if you cannot get an appointment.

Do not stop your medication on your own because of this story. Talk to your prescriber. Stopping a GLP-1 carries its own risks.

Tell your prescriber if you have ever had NAION, unexplained vision loss in one eye, sleep apnea, or if you take sildenafil or tadalafil.

Ask whether your medication is a brand-name drug or a compounded one, and where it comes from.

Look up your prescriber’s license on your state board’s website. Look up the medical director’s license too.

MedSpa Board certification verifies who is prescribing and who is supervising your weight loss program

The MedSpa Board certifies practices on licensing, medical oversight, and the products and devices they use. A weight loss program is a medical practice. It needs a licensed prescriber who screens patients, explains the risks that matter, and is accountable when something goes wrong.

If you run a medspa and your standards are ready to be verified, begin your application now. If you want to see where you stand first, download our free checklist that tells you all the requirements to become certified.

— Kate Dee, MD

Sources & further reading

Dr. Kate Dee
Dr. Kate Dee is a Yale-educated physician and founder of the Medspa Board. She is passionate about educating people about the benefits of aesthetics treatments while avoiding the risks and shady practices.
Back to Blog

Medspa Board certification helps licensed med spas stand out by building trust, attracting high-quality clients, and showcasing verified credentials. We help consumers identify top quality medspas that emphasize safety and medical excellence.

CONTACT US

© Copyright 2026. The Medspa Board. All Rights Reserved.